Extend your brand profile by curating daily news.

VolitionRx Expands Fujifilm Vet Systems Deal to Bring Feline Cancer Test to Japan

By Advos•
VolitionRx has broadened its Japanese supply agreement with Fujifilm Vet Systems to develop and use its Nu.Q Vet Feline Test, targeting a market with nearly 9 million cats and extending the company's canine cancer screening technology to earlier feline lymphoma detection.
VolitionRx Expands Fujifilm Vet Systems Deal to Bring Feline Cancer Test to Japan

VolitionRx Limited, a multinational epigenetics company, has expanded its supply agreement with Fujifilm Vet Systems Co. Ltd. in Japan to include the development and use of its Nu.Q Vet Feline Test, according to a company announcement. The move extends a partnership that already brought the Nu.Q Vet Canine Test to the Japanese market, where growing veterinary demand prompted the introduction of an automated version earlier this year.

The expansion matters because it signals that Volition's blood-based cancer screening approach, already commercialized for dogs in Japan, may soon reach cats, a population in Japan that approaches 9 million. The company said the expanded agreement presents a potential revenue opportunity in that market. For investors tracking VolitionRx Limited (NYSE American: VNRX), the deal offers a concrete path toward a second veterinary product line in a single geography.

The feline expansion follows research demonstrating high accuracy for a prototype feline assay in detecting lymphoma, the most common cancer in cats. Fujifilm plans to conduct an additional study with veterinary oncologists in Japan, a step that could further validate the test before broader clinical adoption. Volition said it is continuing product development of the blood-based feline cancer test, with plans to launch it on the Immunodiagnostic Systems (IDS) i10 automated analyzer platform.

The broader ambition is to make cancer screening a routine component of annual veterinary wellness examinations, extending the company's existing canine testing technology to address the need for earlier cancer detection in cats. That goal aligns with Volition's stated mission of saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, the company is developing and commercializing simple, easy-to-use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and conditions associated with NETosis, such as sepsis.

The agreement also highlights how veterinary diagnostics is becoming a growth channel for epigenetics-based testing. If the feline assay clears further study and reaches the IDS i10 platform as planned, Volition would be positioned to serve Japanese clinics with an automated, blood-based option for detecting lymphoma in cats, a condition that is often diagnosed late. The company noted that a full press release on the agreement is available through https://ibn.fm/6fgSw, and further information about the company is available on its website at Volition.

The announcement was distributed through InvestorWire, part of the Dynamic Brand Portfolio at IBN. The platform provides wire-grade press release syndication along with services that include editorial syndication to 5,000+ outlets and social media distribution to millions of followers. Full terms of use and disclaimers are posted at https://www.InvestorWire.com/Disclaimer.

Advos

Advos

@advos